Achieving lipid goals in Europe: how large is the treatment gap?
- 1 May 2004
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Cardiovascular Therapy
- Vol. 2 (3) , 431-449
- https://doi.org/10.1586/14779072.2.3.431
Abstract
Despite the established benefits of decreasing low-density lipoprotein cholesterol levels in reducing morbidity and mortality from coronary heart disease, not all patients who would benefit from lipid-lowering therapy are being managed appropriately. An in-depth review of the literature (2000-2003) demonstrates that the 'treatment gap' varies across different clinical settings. Although the use of lipid-lowering agents has increased in recent years, there continues to be a widespread failure in the achievement of recommended lipid levels. A combination of the use of the most efficacious statins, together with intervention strategies to ensure that all eligible individuals receive appropriate treatment to achieve lipid goals, are important considerations in minimizing the burden of dyslipidemia in Europe.Keywords
This publication has 54 references indexed in Scilit:
- Gap between guidelines and management of patients with acute coronary syndrome without persistent ST elevation. Finnish prospective follow-up surveyScandinavian Cardiovascular Journal, 2003
- Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE) *Published by Elsevier ,2002
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialPublished by Elsevier ,2002
- Use of statins in the secondary prevention of coronary heart disease: is treatment equitable?Heart, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Secondary prevention of hypercholesterolaemia: results of an audit conducted in South WalesHeart, 2000
- How well are patients with atherosclerotic disease treated?Secondary prevention in primary careScandinavian Journal of Primary Health Care, 2000
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with DyslipidemiaNew England Journal of Medicine, 1987
- THE RESPONSE OF PATIENTS WITH CONGESTIVE HEART FAILURE TO A RAPID ELEVATION IN ATMOSPHERIC TEMPERATURE AND HUMIDITYThe Lancet Healthy Longevity, 1952